Meeting
2013 ASCO Annual Meeting
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
Authors
Georg A. Bjarnason
Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
Georg A. Bjarnason , Naveen S. Basappa , Jennifer J. Knox , Christian K. Kollmannsberger , M. Neil Neil Reaume , Pawel Zalewski , Robyn Jane Macfarlane , Mary J. MacKenzie , Sebastien J. Hotte , Daniel Yick Chin Heng , Denis Soulieres , Jessie Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01499121
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS4594)
DOI
10.1200/jco.2013.31.15_suppl.tps4594
Abstract #
TPS4594
Poster Bd #
34F
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.
First Author: Sudeep Gupta
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2017 ASCO Annual Meeting
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.
First Author: Georg A. Bjarnason
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu